ZOLYMBUS™ (bimatoprost ophthalmic gel) 0.01% is a once-daily drop taken in the evening, often before bed.1
Convenient, single-dose containers make it easier to track doses to help ensure compliance.1
For US Healthcare Professionals only | Patients & Caregivers | Full Prescribing Information | Important Safety Information
INDICATIONS AND USAGE
ZOLYMBUS™ (bimatoprost ophthalmic gel) 0.01%, is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Known hypersensitivity to bimatoprost or any other ingredients in this product.
WARNINGS AND PRECAUTIONS
Bimatoprost may cause changes to pigmented tissues. Most frequently reported changes are increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as bimatoprost is administered. Iris pigmentation is likely to be permanent. Eyelid skin darkening and eyelash changes may be reversible.
Bimatoprost may cause gradual change to eyelashes including increased length, thickness, and number of lashes. These changes are usually reversible upon discontinuation of treatment.
Prostaglandin analogs, including bimatoprost, have been reported to cause intraocular inflammation. ZOLYMBUS should be used with caution in patients with active intraocular inflammation (e.g., iritis/uveitis) because inflammation may be exacerbated.
Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic products. ZOLYMBUS should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
Contact lenses should be removed prior to the administration of ZOLYMBUS and may be reinserted 15 minutes after administration.
ADVERSE REACTIONS
Most common adverse reactions (≥10%) are conjunctival hyperemia (14%) and eye irritation (11%).
Please click here for the full Prescribing Information.
References: 1. ZOLYMBUS™ [prescribing information]. Thea Pharma Inc.; 2025. 2. Polzer H, Elena P, Senge J, inventors. Drippable ophthalmic bimatoprost gel. European patent EP3103439 (B1). August 7, 2019.
ZOLYMBUS is a trademark of Laboratoires Théa.
Copyright ©2026 Thea Pharma Inc. All Rights Reserved. PRC-EN-3014-v2 08.2026